0.23p+0.00 (+0.00%)01 May 2025, 09:28
Jump to:
Theracryf PLC Fundamentals
Company Name | Theracryf PLC | Last Updated | 2025-05-01 |
---|---|---|---|
Industry | Biotechnology | Sector | Healthcare |
Shares in Issue | 2.130 bn | Market Cap | £4.79 m |
PE Ratio | 0.00 | Dividend per Share | 0 |
Dividend Yield | 0 | Dividend Cover | 0 |
EPS | -£0.01 | EPS Growth (%) | 0 |
PEG | 0 | DPS Growth (%) | 0 |
Debt Ratio | 0 | Debt Equity Ratio | 0 |
Asset Equity Ratio | 1.1750 | Cash Equity Ratio | 0.4501 |
Quick Ratio | 3.4454 | Current Ratio | 4.36 |
Price To Book Value | 1.7960 | ROCE | 0 |
Theracryf PLC Dividends
Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
---|
Theracryf PLC Company Financials
Assets | 2024 | 2023 | 2022 |
---|---|---|---|
Tangible Assets | 0 | £3,000.00 | £5,000.00 |
Intangible Assets | £34,000.00 | £43,000.00 | £53,000.00 |
Investments | 0 | 0 | 0 |
Total Fixed Assets | £35,000.00 | £46,000.00 | £58,000.00 |
Stocks | 0 | 0 | 0 |
Debtors | £497,000.00 | £43,000.00 | £13,000.00 |
Cash & Equivalents | £2.00 m | £5.00 m | £9.03 m |
Other Assets | £1,000.00 | 0 | 0 |
Total Assets | £3.06 m | £6.17 m | £9.64 m |
Liabilities | 2024 | 2023 | 2022 |
---|---|---|---|
Creditors within 1 year | £723,000.00 | £833,000.00 | £411,000.00 |
Creditors after 1 year | -£2,000.00 | 0 | 0 |
Other Liabilities | 0 | 0 | 0 |
Total Liabilities | £721,000.00 | £833,000.00 | £411,000.00 |
Net assets | £2.34 m | £5.34 m | £9.23 m |
Equity | 2024 | 2023 | 2022 |
---|---|---|---|
Called up share capital | £687,000.00 | £687,000.00 | £687,000.00 |
Share Premium | £27.87 m | £27.87 m | £27.87 m |
Profit / Loss | -£3.57 m | -£5.01 m | -£3.17 m |
Other Equity | £2.34 m | £5.34 m | £9.23 m |
Preference & Minorities | 0 | 0 | 0 |
Total Capital Employed | £2.34 m | £5.34 m | £9.23 m |
Ratios | 2024 | 2023 | 2022 |
---|---|---|---|
Debt Ratio | 0 | 0 | 0 |
Debt-to-Equity | 0 | 0 | 0 |
Assets / Equity | 1.1750 | 1.1750 | 1.1750 |
Cash / Equity | 0.4501 | 0.4501 | 0.4501 |
EPS | -£0.01 | -£0.01 | -£0.01 |
Cash Flow | 2024 | 2023 | 2022 |
---|---|---|---|
Cash from operating activities | -£3.00 m | -£4.13 m | -£2.58 m |
Cashflow before financing | 0 | 0 | 0 |
Increase in Cash | -£3.00 m | £490,000.00 | -£1.08 m |
Income | 2024 | 2023 | 2022 |
---|---|---|---|
Turnover | £396,000.00 | £442,000.00 | 0 |
Cost of sales | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 |
Operating Profit | -£3.57 m | -£5.10 m | -£3.19 m |
Pre-Tax profit | -£3.57 m | -£5.01 m | -£3.17 m |
Theracryf PLC Company Background
Sector | Healthcare |
---|---|
Activities | TheraCryf PLC is a clinical-stage biotechnology company focused on profitable segments in oncology and neuropsychiatry. The company's lead clinical asset, SFX-01 is a patented form of delivering sulforaphane, which could be used in the treatment of a number of cancers, neurodevelopmental disorders, and other diseases. |
Latest Interim Date | 28 Nov 2024 |
Latest Fiscal Year End Date | 28 May 2025 |
Theracryf PLC Directors
Appointed | Name | Position |
---|---|---|
2025-02-21 | Dr. Huw Jones | Executive Director,Chief Executive Officer |
2025-02-19 | Dr. Susan Elizabeth Foden | Non-Executive Director,Chairman |
2017-06-23 | Mr. John Bradshaw | Executive Director,Finance Director and Company Secretary |
2020-04-30 | Dr. Stephen Joseph Franklin | Executive Director,Chief Executive Officer |
2024-05-30 | Mr. Richard Anthony Moulson | Executive Director,Chief Financial Officer |
2017-04-03 | Dr. Mark Andrew Wyatt | Non-Executive Director |
2023-09-05 | Mr. Barry Clare | Executive Director,Chairman |
2018-11-08 | Dr. Marc Francois d’Abbadie | Non-Executive Director |
2025-02-21 | Dr. Alan John Barge | Non-Executive Director,Senior Independent Director |
2023-12-28 | Ms. Susan Elizabeth Clement-Davies | Non-Executive Director |
2025-02-21 | Mr. Toni Markus Antero Hanninen | Executive Director,Chief Financial Officer |
2025-02-21 | Dr. Alastair Maclaughlin Smith | Non-Executive Director,Chairman |
Theracryf PLC Contact Details
Company Name | TheraCryf PLC |
---|---|
Address | Liverpool Science Park Innovation Centre 2, 146 Brownlow Hill, Liverpool, L3 5RF |
Telephone | |
Website | https://www.evgen.com |
Theracryf PLC Advisors
Auditor | RSM UK Audit LLP |
---|---|
Phone | +44 1516002600 |
Remuneration Consultant | PricewaterhouseCoopers LLP |
---|---|
Phone | +44 205835000 |
Fax | +44 208224652 |
Stockbroker | Northland Capital Partners |
---|---|
Phone | +44 2038616625 |
Fax | +44 2076005975 |
Registrar | S.L.C Registrars Ltd |
---|---|
Phone | +44 1903706150 |
Nominated Adviser | Northland Capital Partners |
---|---|
Phone | +44 2038616625 |
Fax | +44 2076005975 |
Financial PR Adviser | Buchanan |
---|---|
Phone | +44 2074665000 |
Fax | +44 2074665001 |
Solicitor | Pinsent Masons LLP |
---|---|
Phone | +44 2074187000 |
Fax | +44 2074187050 |
Solicitor | Theobald Associates |
---|---|
Phone | +44 2073978434 |
Fax | +44 2073978400 |
Stockbroker | Stockdale Securities Ltd |
---|---|
Phone | +44 2076016100 |
Nominated Adviser | Stockdale Securities Ltd |
---|---|
Phone | +44 2076016100 |
Most Read
Receive our
daily news email
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine

Plus more useful investment content and occasional promotional offers.
Market Overview
UK 350 Risers and Fallers
Risers
Company | Price | % Chg |
---|---|---|
Ferrexpo PLC | 72.00 | 22.24 |
Genus PLC | 1,992.00 | 8.14 |
St. James's Place PLC | 1,003.00 | 6.79 |
Aberdeen Group PLC | 156.50 | 6.03 |
Whitbread PLC | 2,743.00 | 5.78 |
Wizz Air Holdings PLC | 1,718.00 | 5.66 |
Fallers
Company | Price | % Chg |
---|---|---|
4Imprint Group PLC | 3,070.00 | -9.71 |
Clarkson PLC | 2,995.00 | -8.83 |
Hochschild Mining PLC | 272.00 | -3.61 |
Coats Group PLC | 70.00 | -3.31 |
Lloyds Banking Group PLC | 71.34 | -2.65 |
Elementis PLC | 122.00 | -2.56 |
Risers/fallers data from previous trading day. Today's data available from 8:15am.